Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why AstraZeneca Could Be a Sound Long-Term Bet:
https://www.barrons.com/articles/why-astrazeneca-could-be-a-sound-long-term-bet-51645608699
$SIGY - Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or Vaccines.
Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”), a medical technology company focused on the treatment of pathogen-related conditions that precipitate sepsis, today released the following note authored by its Chairman and CEO, Jim Joyce.
https://finance.yahoo.com/news/sigyn-therapeutics-ceo-note-omicron-133000484.html
Covid19 Masks Alpha Pro Tech, Ltd. (NYSE: APT) together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. Reported last month financial results for the three and six months ended June 30, 2021. Lloyd Hoffman, President and Chief Executive Officer of Alpha Pro Tech, commented, "Through the second quarter, we witnessed the softening in demand for our N-95 particulate respirator face mask and face shield sales, consistent with our guidance provided in our first quarter earnings release. Sales for these products declined to be more in line with pre-pandemic quarterly levels and we currently expect similar trends going forward. There is a potential for mask sales to increase again as a result of the recent increased spread of Covid-19, primarily due to the Delta variant. However, due to the inherent uncertainty of the unprecedented and rapidly evolving situation, we are unable to predict with any certainty the likelihood of this on our future operations." $APT
$CEMI Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
$CEMI HIV Diagnostics Market Revenue to Cross USD 760 Mn by 2027: Global Market Insights Inc.
$CEMI here we go
$CEMI Market Cap $70.747M
$CEMI Top Institutional Holders
Holder Shares Date Reported % Out Value
Vanguard Group, Inc. (The) 855,245 Jun 29, 2021 2.99% 2,540,077
Segall Bryant & Hamill LLC 703,248 Jun 29, 2021 2.46% 2,088,646
Royce & Associates LP 491,453 Jun 29, 2021 1.72% 1,459,615
Penbrook Management, LLC 355,270 Jun 29, 2021 1.24% 1,055,151
Perkins Capital Management, Inc. 267,980 Jun 29, 2021 0.94% 795,900
Millennium Management LLC 251,869 Jun 29, 2021 0.88% 748,050
Blackrock Inc. 199,249 Jun 29, 2021 0.70% 591,769
Geode Capital Management, LLC 144,622 Jun 29, 2021 0.51% 429,527
Tibra Equities Europe Ltd 109,000 Jun 29, 2021 0.38% 323,730
Ameriprise Financial, Inc. 103,253 Jun 29, 2021 0.36% 306,661
https://finance.yahoo.com/quote/CEMI/holders?p=CEMI
$CEMI Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
FDA Emergency Use covid19 ( $CEMI ) Nod For Its Partner's LumiraDX COVID-19 Antibody Test
$IBIO established oncology drug pipeline with 3 new antibody programs.
#Covid19 Vaccine Maker $IBIO Top Mutual Fund Holders
Holder Shares Date Reported % Out Value
Vanguard Total Stock Market Index Fund 6,182,400 Mar 30, 2021 2.84% 9,520,896
iShares Russell 2000 ETF 4,868,109 May 30, 2021 2.23% 7,058,758
Vanguard Extended Market Index Fund 2,725,700 Mar 30, 2021 1.25% 4,197,578
Fidelity Small Cap Index Fund 1,655,392 Apr 29, 2021 0.76% 2,267,887
iShares Russell 2000 Growth ETF 1,586,587 May 30, 2021 0.73% 2,300,551
Fidelity Extended Market Index Fund 1,144,666 May 30, 2021 0.53% 1,659,765
iShares Micro Cap ETF 574,587 May 30, 2021 0.26% 833,151
Schwab Capital Trust-Small Cap Index Fund 456,189 Apr 29, 2021 0.21% 624,978
iShares Core S&P Total U.S. Stock Market ETF 429,442 May 30, 2021 0.20% 622,690
TIAA-CREF Funds-Small-Cap Blend Index Fund 370,538 Apr 29, 2021 0.17% 507,637
https://finance.yahoo.com/quote/IBIO/holders?p=IBIO
$IBIO iBio, Inc.“iBio is a global leader in plant-based biologics manufacturing. Its FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary products which include biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.
https://finance.yahoo.com/news/ibio-reports-successful-preclinical-immunization-211000069.html
CV Sciences, Inc. $CVSI http://www.cvsciences.com
$MJNA From candy and chocolate to infused beverages, the cannabis edibles market will hit $4.1 billion by 2022 according to a research report from ArcView.
$MJNA First Company to have Cannabis Products Subsidized by Mexican Government
In August 2017, the State of Mexico became the first state in the country to subsidize CBD products for its citizens, agreeing to purchase THC-free Real Scientific Hemp Oil™-X (RSHO™-X) from MJNA international subsidiary HempMeds® Mexico for individuals suffering from a variety of serious indications. https://www.medicalmarijuanainc.com/company-of-firsts/first-company-cannabis-products-subsidized-mexican-government/
$MJNA First to Introduce Cannabinoid Foods and Supplements to the Mainstream Marketplace
Recognizing the need for a national cannabinoid market to create access to cannabinoids to as many people as possible, despite the legal challenges, Medical Marijuana, Inc. began researching ways to bring cannabis-based products to a wider customer base. https://www.medicalmarijuanainc.com/company-of-firsts/the-first-to-introduce-cannabinoids-to-the-mainstream-marketplace/
$MJNA First to Introduce Cannabinoid Foods and Supplements to the Mainstream Marketplace
Recognizing the need for a national cannabinoid market to create access to cannabinoids to as many people as possible, despite the legal challenges, Medical Marijuana, Inc. began researching ways to bring cannabis-based products to a wider customer base. https://www.medicalmarijuanainc.com/company-of-firsts/the-first-to-introduce-cannabinoids-to-the-mainstream-marketplace/
$IBIO IBio and Fraunhofer USA Conclude Litigation and Enter License Agreement
$MJNA Net Income of $3.7 Million in 2021 First Quarter Financial and Operational Results
$PSCBF $CSE:PAS - Awarded National Cancer Institute Grant For Leukemia Program
$IDEX Powering the Largest Wireless Fleet in the U.S.
WAVE’s high power wireless charging systems offer a modular solution (125kW to 500kW) across a broad range of commercial applications, including mass transit, ports, warehouse and distribution centers. The largest electric mass transit bus fleet in the US is powered by WAVE.
https://ideanomics.com/
$MJNA Medical Marijuana, Inc., an investment holding company, operates in the cannabinoid-based nutraceutical industry. It focuses on the development, sale, and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol (CBD) and other products containing CBD-rich hemp oil; treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products; and nonpsychoactive cannabidiol products. The company is also involved in the research and development of new therapeutic agents that are designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants; dietary supplements, skin care products, and prescription-based hemp oil under the Kannaway and HempMeds brands; and proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods for the medicinal cannabinoid industry. In addition, it offers RSHO oil for the treatment of various illnesses and conditions; and plant-based, non-GMO pet products for health and wellness, play and wear, and environmentally-friendly supplies. Medical Marijuana, Inc. was incorporated in 2005 and is based in San Diego, California. https://finance.yahoo.com/quote/MJNA?p=MJNA&.tsrc=fin-srch
$PFE Pfizer #Covid19 Vaccine maker
Ghp noetic science guys ... check it out !!!
With the guy that started, helped fund and was a director of the 200 Billion dollar fund-managing Nasdaq Firm,
known as The Carlyle Group (Edward Mathias, who just retired),
known from 2016 filings to have been a 24% owner of the Private Biotech started in 2013,
started with Dr. Michael W Fountain in 2013 (search his resume, 131 issued US patents, etc on the $NDTP Ibox and CCA, LLC blog site),
that is now R/M with the OTC shell (not for long now) that has a new name and ticker,
$NDTP Nano Delivery Technology Pharmaceuticals Inc, and knowing that Edward Mathias is(or was) a director of the Univ of Penn IP-Patent asset Trust, with over apx 30,000 patents pending and issued, the same UPennMed Univ (Perelman Traumatic Brain Injury medical center at UPennMed) that they have a 7 year old #TBI Tramatic Brain Injury JV-Research contract with that started based om 2010 R&D that Professor Michael W Fountain was at the early core of,
And then seeing this pop in the News listing the Same Edward Mathias as the Chairman here:
https://www.businesswire.com/news/home/20201006005261/en/Catalio-Capital-Management-LP-Closes-Oversubscribed-Venture-Fund-II-at-100-Million-Hard-Cap
Does any one have any doubts left where $NDTP is going with just a 292,000 share float, $4.00 share price, and a CE-OTC skull and cross bones left from the 11 year old shell they took over from a Court ordered Custodian saving of the shell, to set up for a move to the NYSE with Billion dollar Biotech birth to shell when the SEC 1-A(S-1) filing drops on Edgar????
Biggest dry Powder keg arsenal I have seen in 45 years.
The float is only 1.2 Million dollars, for a 292,000 float, held back by the lack of the final filing and removal of the 15-12G SEC filing that protected the shell, and the going back to full SEC filings.
Three of the know Principles were directors, officer of three Billion dollar Nasdaq and NYSE firms for 1-2 decades already.
Check this out, look for the bio and the CEO of this, it is NDTP's Edward Mathias!!!
https://www.businesswire.com/news/home/20201006005261/en/Catalio-Capital-Management-LP-Closes-Oversubscribed-Venture-Fund-II-at-100-Million-Hard-Cap
$PMCB Bio-Artificial Pancreas for Diabetes
"We plan to develop a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Our therapy involves encapsulation of human cells that have been genetically engineered to produce, store insulin and release insulin on demand at levels in proportion to the levels of blood sugar (glucose) in the human body. We also plan to explore the encapsulation of human stem cells and beta islet cells as an alternative to using genetically modified human liver cells. The encapsulation will be done using the Cell-in-a-Box® technology.
Insulin-producing cells (HIT-T15) have already been encapsulated using the sodium cellulose sulfate-based technology found in Cell-in-a-Box®. Encapsulation did not affect cell viability or insulin production. In cell culture, the encapsulated cells were able to detect the glucose concentration in a nutrient solution and react in a proper way by producing insulin. In the opinion of the authors of the study, encapsulation of insulin-producing cells with sodium cellulose sulfate, which is more biocompatible and less immunogenic than other encapsulation materials, seemed to be a promising method for the immunoisolation of porcine beta islet cells for xenotransplantation to replace the endocrine pancreas. Schaffellner S., et al.
Transplantation Proc., Vol. 37, 248-252 (2005)
In an effort to avoid the use of non-human islet cells in its diabetes treatment, PharmaCyte has obtained from the University of Technology Sydney (“UTS”) in Australia an exclusive, worldwide license to use insulin-producing genetically engineered human liver cells developed by UTS to treat Type 1 diabetes and insulin-dependent Type 2 diabetes. These cells, named “Melligen,” have already been tested in mice and shown to produce insulin in direct proportion to the amount of glucose in their surroundings. In fact, when Melligen cells were transplanted into immosuppressed diabetic mice, their blood glucose levels became normal. The Melligen cells reversed the diabetic condition.
Melligen cells can be readily grown in culture and are available in unlimited supply. Compared to native pancreatic beta islet cells, Melligen cells are much more resistant to the pro-inflammatory cytokines that have been shown to be involved in beta islet cell death. We believe that this property makes them an ideal potential candidate cell line for beta islet cell replacement therapy with the prospect to achieve long-term transplant graft function. However, further research and development (“R&D”) needs to be done with the Melligen cells to insure they function as reported in the literature by UTS.
PharmaCyte has acquired from Austrianova an exclusive, worldwide license to use the Cell-in-a-Box® technology for the development of a treatment for diabetes. We believe that encapsulating the Melligen cells using Cell-in-a-Box® live cell encapsulation technology has numerous advantages over encapsulation of cells with other materials, such as alginate. Since our capsules are composed largely of cellulose (a bio-inert material in the human body), the Cell-in-a-Box® capsules are durable, resilient and long-lasting when compared to the competition. They remain intact for long periods of time in the body, all the while protecting the cells inside them from immune system attack. Also, in prior studies these capsules and the cells inside them have not caused any immune or inflammatory responses like those seen with alginate-encapsulated cells. Studies have shown that the Cell-in-a-Box encapsulation process does not reduce the capability of the Melligen cells to produce insulin."
https://pharmacyte.com/live-cell-encapsulation/diabetes/
$APHA medical cannabis powered by sunlight. https://aphria.ca/
$PMCB PharmaCyte Biotech Successfully Completes 9-Month Stability Study
https://finance.yahoo.com/news/pharmacyte-biotech-successfully-completes-9-141500362.html
$TLRY first GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers on five continents. https://www.tilray.com/
$MJNA MACD BUllish Crossover
$TLRY Monday BREAKOUT
$RVVTF and $OPK may be two of the next Covid19 dug and #VitaminD drug winners to get #FDA EUA $approval for treating #Covid19.
And Dr. Mark Kester of Keystone Nano was listed as a Team member days ago on the $NDTP website. Hmmm.
http://NDTPharma.com/team
Either way this great news for $NDTP shareholders. Mega Biotech with a possible out of the box drink line that could inhibit #TBI Traumatic Brain Injury!